Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective

Seng WK 1 , Hwang SJ , Han DC , Teong CC , Chan J , Burke TA Show all authors , Carides GW , Choi YJ

Affiliations 

  • 1 Department of Nephrology, Singapore General Hospital, Singapore
Nephrology (Carlton), 2005 Oct;10(5):520-4.
PMID: 16221106

Abstract

To evaluate losartan and conventional antihypertensive therapy (CT) compared with CT alone on the cost associated with end-stage renal disease (ESRD) in Hong Kong, Japan, Korea, Malaysia, Singapore and Taiwan.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications